New concepts and tools in imaging for the study of neurodegenerative disease.
Existing technologies permit the detection of changes in neurotransmitter and/or neuroreceptor expression. This may be useful for diagnosis, for monitoring disease progression, and for assessing the pathogenesis of complications associated with long-term treatment. Although the binding of [11C]raclopride to D2 receptors is subject to competition from endogenous dopamine, this can be exploited to estimate changes in synaptic levels of dopamine. Assessment of processes downstream to the receptor will require the development of new approaches.
Stoessl
A J
AJ
Pacific Parkinson's Research Centre, University of British Columbia, Vancouver Hospital & Health Sciences Centre, Vancouver, BC, Canada. jstoessl@interchange.ubc.ca
Lee
C S
CS
de la Fuente-Fernandez
R
R
D002250:Carbon Radioisotopes; D017690:Cell Transplantation / Q000473:pathology; D003952:Diagnostic Imaging / Q000379:methods* / Q000639:trends*; D018450:Disease Progression; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D006801:Humans; D019636:Neurodegenerative Diseases / Q000175:diagnosis* / Q000378:metabolism / Q000503:physiopathology* / Q000628:therapy; D018377:Neurotransmitter Agents / Q000378:metabolism; D020891:Raclopride; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D011984:Sensory Receptor Cells / Q000378:metabolism
D002250:Carbon Radioisotopes; D018492:Dopamine Antagonists; D018377:Neurotransmitter Agents; D017448:Receptors, Dopamine D2; D020891:Raclopride; D004298:Dopamine